Lv1
70 积分 2025-03-12 加入
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
14小时前
已完结
Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study
9天前
已完结
Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial
9天前
已完结
Cutaneous Adverse Events and Cancer Survival Prognosis With Immune Checkpoint Inhibitor Treatment
15天前
已完结
Seasonal and geographic variation in cutaneous immune‐related adverse events after treatment with immune checkpoint inhibitors
15天前
已完结
The coming decade in precision oncology: six riddles
20天前
已完结
Systemic immunity in cancer
26天前
已完结
Seasonal patterns of toxicity in melanoma patients treated with combination anti-PD-1 and anti-CTLA-4 immunotherapy
1个月前
已完结
Seasonal patterns of toxicity in melanoma patients treated with combination anti-PD-1 and anti-CTLA-4 immunotherapy
1个月前
已完结
Season of cancer diagnosis exerts distinct effects upon short‐ and long‐term survival
1个月前
已完结
皖公网安备34019202002308
